- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07939217
Collection and Storage of Biological Samples From Patients Affected by Uveitis for Immunological and Multi-omic Studies (UVEOMICS)
Uveitis is a group of eye diseases that cause inflammation and may lead to vision loss. The biological processes responsible for these diseases are not fully understood, particularly in rare forms of uveitis.
The purpose of UVEOMICS is to collect and store biological samples and clinical information from adults with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. Researchers will study these samples to better understand the causes of eye inflammation and identify biological markers that may help improve diagnosis, monitor disease activity, predict relapses, and guide future treatments.
The study plans to enroll approximately 2,000 adults, including 1,500 patients with uveitis and 500 individuals undergoing cataract surgery who will serve as a comparison group.
Participants may provide blood samples and small samples of fluid from inside the eye (aqueous humor or vitreous fluid), when appropriate. Samples and clinical information may be collected at different stages of the disease and during follow-up visits. Biological samples will be stored for future research and analyzed together with clinical findings and eye imaging results.
This is an observational study. Participation will not change the medical care or treatment participants receive.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Maria Vittoria Cicinelli
- Phone Number: +3902264332648
- Email: cicinelli.mariavittoria@hsr.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will include approximately 2,000 adults recruited at the IRCCS Ospedale San Raffaele in Milan, Italy.
Approximately 1,500 participants will be patients diagnosed with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. An additional 500 participants will be adults without uveitis undergoing elective cataract surgery, who will serve as a comparison group.
Participants will be recruited consecutively during routine outpatient visits, hospital admissions, and diagnostic or surgical procedures. Patients with uveitis may provide biological samples at different stages of their disease, including active inflammation, remission, and relapse.
Recruitment will be non-probabilistic and will include eligible adults regardless of sex or ethnicity who provide written informed consent.
Description
Inclusion Criteria:
For patients with uveitis:
Age 18 years or older.
Clinical diagnosis of infectious or non-infectious uveitis (anterior, intermediate, posterior, or panuveitis), including rare white dot syndromes such as multiple evanescent white dot syndrome (MEWDS), punctate inner choroidopathy (PIC), idiopathic multifocal choroiditis (iMFC), acute zonal occult outer retinopathy (AZOOR), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), and serpiginoid chorioretinitis.
Ability to understand and provide written informed consent.
Willingness to provide biological samples (blood and/or aqueous humor and/or vitreous humor, when clinically indicated) and associated clinical information.
Exclusion Criteria:
Age younger than 18 years.
Severe systemic conditions that make biological sample collection unsafe, such as uncontrolled diabetes, systemic infections, or inability to be seated at the slit lamp.
Inability to provide valid informed consent.
Refusal to participate or withdrawal of informed consent.
Pregnancy or breastfeeding if these conditions contraindicate the planned biological sampling.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
uveitis patients
uveitis patients |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of biological samples collected and stored in the UVEOMICS biobank
Time Frame: Throughout the study period (approximately 6 years).
|
The total number of biological samples (blood, aqueous humor, and vitreous humor, when clinically available) collected, processed, and stored from enrolled participants for future immunological and molecular research. Samples will be linked to clinical and imaging data and may be collected at different stages of disease activity. |
Throughout the study period (approximately 6 years).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UVEOMICS
- UVEOMICS (Other Identifier: IRCCS SAN RAFFAELE)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.